Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin N. Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth Ngo, Varunika Savla, Yixiang Li, Muhannad Abu-Remaileh, Xinyue Li, Marie-Anais Locquet, Bishma Tuladhar, Ranya Odeh, Frances Hamkins-Indik, Daphne He, Miles W. Membreno, Meisam Nosrati, Nathan N. Gushwa, Siegfried S. F. Leung, Breena Fraga-Walton, Luis Hernandez, Miguel P. Baldomero, Bryan M. Lent, David Spellmeyer, Joshua F. Luna, Dalena Hoang, Yuliana Gritsenko, Manesh Chand, Megan K. DeMart, Sammy Metobo, Chinmay Bhatt, Justin A. Shapiro, Kai Yang, Nathan J. Dupper, Andrew T. Bockus, Jinshu Fang, Ramesh Bambal, Peadar Cremin, John G. Doench, James B. Aggen, Li-Fen Liu, Bernard Levin, Evelyn W. Wang, Iolanda Vendrell, Roman Fischer, Benedikt Kessler, Prafulla C. Gokhale, Sabina Signoretti, Alexander Spektor, Constantine Kreatsoulas, Marie Evangelista, Rajinder Singh, David J. Earp, Deepak Nijhawan, Pablo D. Garcia, Matthew G. Oser. "Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors." Nature (2025). https://doi.org/10.1038/s41586-025-09433-w